Early data for Avidity's RNA therapy show possible functional benefit in muscular dystrophy

Early data for Avidity's RNA therapy show possible functional benefit in muscular dystrophy

Submitted by admin on June 12, 2024 - 11:19pm
Source: 
Fierce Biotech
News Tags: 
Avidity Biosciences
RNA
AOC 1020
del-brax
FSHD
clinical trials
Headline: 
Early data for Avidity's RNA therapy show possible functional benefit in muscular dystrophy
snippet: 

Avidity Biosciences’ AOC 1020, newly dubbed del-brax, demonstrated a safe profile and was tied to functional improvement among people with facioscapulohumeral muscular dystrophy (FSHD) in a phase 1/2 trial.

Do Not Allow Advertisers to Use My Personal information